Overview of Dolopar

The following table provides a quick overview of the medicine commonly known as Dolopar.

Property	Description
Active ingredient	Paracetamol (Acetaminophen)
Form	Tablet, Oral Suspension
Pharmacological class	Analgesic and Antipyretic
General purpose	Relief from discomfort and fever
Origin	Synthetic

Identity and Pharmacological Class

Dolopar is a specific brand of medicine whose active ingredient is Paracetamol, which is globally known as Acetaminophen in the U.S. This synthetic compound belongs to the pharmacological class of Non-Opioid Analgesics and Antipyretics. Its function is to reduce pain and lower a high body temperature. Its widespread use for symptoms such as general body aches and headache discomfort is clinically recognized and confirmed across numerous regulatory bodies worldwide.

Composition and Forms

Paracetamol is the main component of Dolopar, and the medicine is most frequently administered orally, available in popular forms such as scored tablets and liquid oral suspensions. The medication can be found either as a single product containing only Paracetamol, or as a combination product, where it may include a secondary active component, such as Caffeine, to enhance the pain-relieving effect. The manufacturing focuses on combining the active ingredient with a neutral base suitable for either easy swallowing or convenient dosage.

The General Principle of Action

The core principle behind Dolopar's effect is its action within the central nervous system—the brain and spinal cord. It operates by reducing the signaling pathways that communicate pain and assists the brain’s temperature-regulating center in achieving a more normal setting during a fever. This systemic function is pharmacologically verified to relieve generalized discomfort, making it a reliable choice for managing common, non-specific aches and elevated temperatures.

What side effects are possible with Dolopar?

Possible side effects and safety information

The safety profile of Dolopar, which contains Paracetamol (Acetaminophen), is documented in official regulatory labeling and is characterized primarily by a low incidence of adverse reactions, with an emphasis on hepatic and immune system constraints.

Adverse effects are officially categorized by their frequency. Rare reactions (occurring in up to 1 in 1,000 users) may include non-specific skin rashes and blood disorders like thrombocytopenia. Very Rare reactions (fewer than 1 in 10,000 users) include severe skin conditions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, as officially documented by regulatory authorities. Reactions affecting the Immune System, such as anaphylactic shock and angioedema, are also reported, often with a frequency classified as Not Known (cannot be estimated from available data).

The most significant safety constraint is the potential for acute liver failure, which is listed as a serious adverse reaction. Use is therefore contraindicated in individuals with severe hepatic impairment or active liver disease. Caution is also advised for patients with severe renal impairment and those in glutathione-depleted states, such as chronic heavy alcohol users, as these conditions may increase the risk of toxicity and metabolic acidosis.

Regarding exposure, regulatory summaries note that prolonged regular daily use of Paracetamol may enhance the effects of blood thinners, and prolonged high-dose treatment carries a potential for renal adverse reactions. Concomitant use with any other Paracetamol-containing product must be strictly avoided to prevent unintentional overdose and the associated risk of liver damage.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented overdose manifestations and mandated emergency procedures for Dolopar (Paracetamol/Acetaminophen), based strictly on government regulatory documents.

Overdose Scope

Documented overdose presentations: Initial signs, such as nausea, vomiting, and abdominal pain, are often non-specific or may be absent during the first 24 hours. The potential for severe hepatotoxicity is often masked during this latent period.

Physiological systems affected (as stated in label): The primary severe effects involve the Hepatic system, leading to liver necrosis and potential hepatic failure, and the Renal system, which may result in acute tubular necrosis. Systemic effects can include metabolic acidosis.

Dose-related or exposure-related factors (if applicable): Toxicity can result from a single acute ingestion or repeated supratherapeutic dosing over time.

Population-specific overdose notes (if applicable): Increased risk of severe toxicity is officially documented in patients with pre-existing liver disease, chronic alcohol misuse, malnutrition, or concurrent use of enzyme-inducing drugs.

Emergency Response Statements

Emergency-response statements (as written in official documents): Immediate medical treatment is essential and required regardless of apparent symptoms. The specific antidote, N-acetylcysteine (NAC), should be administered, optimally within 8 hours of ingestion.

When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention or contact a Poison Control Center right away, even if the individual feels well or is asymptomatic.

Official Overdose Statements

Immediate treatment is essential because initial symptoms of overdose may be mild or absent.
Seek immediate medical attention or contact a Poison Control Center right away, even if the person feels well.
Overdose is known to cause severe, potentially fatal hepatotoxicity leading to liver failure.
The specific antidote, N-acetylcysteine, should be administered within a time-sensitive window.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile by the critical risk of delayed, severe hepatotoxicity and the time-dependent effectiveness of the antidote. This profile strictly mandates that individuals seek immediate medical help following any known or suspected excessive ingestion, regardless of their current condition. The official labeling identifies specific population-based risk factors that can increase the severity of the expected toxic manifestations.

Therapeutic Uses of Dolopar

What Dolopar Treats: Main Uses and Benefits

Dolopar (Paracetamol/Acetaminophen) is commonly applied in therapeutic areas involving symptomatic discomfort related to pain and fever. Its therapeutic application is focused on easing the overall burden of symptoms across several common clinical scenarios. The medication is used to temporarily relieve pain and reduce fever.

The medication plays a role in managing symptoms related to mild-to-moderate discomfort and elevated body temperature (pyrexia). It is relevant for easing symptoms of conditions like tension headaches, toothaches, muscle aches, and episodic discomfort such as menstrual period pain. It is commonly applied in scenarios where additional management of discomfort is required, such as during seasonal colds, influenza-like illnesses, or following routine immunizations.

Its role is relevant in situations such as:

“It is commonly applied in settings where symptoms become temporarily overwhelming.”

By assisting with the management of an elevated temperature and easing pain, the medication contributes to improving day-to-day comfort during symptomatic periods and assists with maintaining functional stability.

Quick Fact: Support for Symptoms Related to Pain and Pyrexia

Quick Fact: Support for Mild-to-Moderate Pain and Pyrexia

Eligibility and Restrictions for Use

Dolopar (paracetamol/acetaminophen) is a widely used pain reliever and fever reducer, but regulatory guidelines strictly limit its use in specific populations to prevent serious harm.

Contraindications and Restrictions

Population Status	Condition/Group Prohibited or Restricted
CONTRAINDICATED	Known hypersensitivity or allergy to paracetamol or any formulation ingredient.
CONTRAINDICATED	Severe hepatic impairment or severe active liver disease.
RESTRICTED	Concurrent use with any other medication containing paracetamol/acetaminophen is prohibited due to the high risk of severe liver damage.
CAUTION	Individuals with chronic alcoholism or those who consume three or more alcoholic drinks daily due to increased hepatotoxicity risk.
CAUTION	Patients with severe renal impairment, chronic malnutrition, or dehydration; dose adjustment may be necessary.
AGE-RELATED	Not recommended for use in children below 12 years for certain tablet formulations.
PREGNANCY/LACTATION	Use during pregnancy requires medical consultation, limited to the lowest effective dose for the shortest duration. Generally considered safe for use during breastfeeding at therapeutic doses.

What should I know about interactions with other medicines?

Dolopar Interactions with other medicines and products

Do not take Dolopar with any other prescription or non-prescription medicine that contains paracetamol/acetaminophen. This is the most critical interaction warning, as combining products containing the same active ingredient significantly increases the risk of exceeding the safe daily dose, which can lead to severe liver damage (hepatotoxicity).

Interaction-related cautions include:

Oral Anticoagulants (e.g., Warfarin): Prolonged, regular use of paracetamol may enhance the anticoagulant effect of coumarins like warfarin, increasing the risk of bleeding. Occasional doses are generally considered to have no significant effect, but monitoring the International Normalized Ratio (INR) may be required with chronic use.
Medicines affecting absorption: The speed of paracetamol absorption may be increased by medicines like Metoclopramide and Domperidone. Conversely, the absorption may be reduced or delayed by Cholestyramine.
Other Drugs: Caution is advised with drugs that can affect liver enzymes, such as certain anti-tuberculosis medications (e.g., Rifampicin, Isoniazid) and some antibiotics (e.g., Chloramphenicol, Flucloxacillin), due to a potential increase in toxicity risk.
Alcohol: Avoid or use alcohol with caution. Chronic alcohol consumption is a major risk factor for serious liver injury when taking paracetamol.

Patients with pre-existing conditions like chronic alcoholism, severe hepatic impairment, or chronic malnutrition are generally at a heightened risk for paracetamol toxicity.

Mechanism of Action

How Dolopar Works: Mechanism of Action

Dolopar exerts its pharmacological effect through the combined, yet distinct, mechanisms of Paracetamol (Acetaminophen) and Caffeine.

Paracetamol primarily acts within the central nervous system (CNS), specifically targeting and inhibiting the cyclooxygenase (COX) enzyme system, likely a central splice variant. This inhibitory action reduces the biosynthesis and release of prostaglandins—key lipid mediators of thermal and nociceptive signaling—in the brain and spinal cord. By decreasing prostaglandin concentration in the hypothalamic heat-regulating center, the body's thermostatic set point is modulated, leading to a physiological decrease in elevated body temperature.

Caffeine acts as an adenosine receptor antagonist, blocking adenosine from binding to its A1 and A2 A receptors, resulting in CNS stimulation. At a systemic level, this action contributes to the vasoconstriction of cerebral blood vessels and may modulate the body's descending pain-inhibitory pathways. Caffeine is also understood to enhance the rate of Paracetamol absorption from the gastrointestinal tract, influencing systemic exposure.

Dosage and Administration Information

How to Use Dolopar: Official Administration Guidelines

Dolopar contains paracetamol (acetaminophen), and its proper use is governed by official regulatory instructions. Adherence to these guidelines is necessary for safe administration.

Administration Scope

Feature	Official Instruction Summary
Route of Administration	Primarily Oral (for tablets, capsules, suspensions, or soluble forms). The active ingredient is also available for Intravenous (IV) use in hospital settings.
Dosing Schedule	Adults and Children 12 years: A single dose is typically 500 mg to 1000 mg. The maximum total amount consumed must not exceed 4000 mg (4 g) in any 24-hour period.
Frequency and Timing	Doses must be separated by a minimum of 4 to 6 hours. Do not take more than four doses within 24 hours.
Preparation Requirements	Oral Suspensions/Liquids must be shaken well before use, and the dose must be measured using the provided device for accuracy. Soluble tablets must be fully dissolved in water.

Administration Rules

Age-Group Rules: Dosing for children is based on body weight (typically 10-15 mg/ kg) and should not exceed the adult limit. Patients with liver impairment must have their maximum daily dose reduced.
Missed Dose: Take the missed dose as soon as remembered, unless it is almost time for the next dose. If so, skip the missed dose and wait the required minimum interval (4 to 6 hours) before taking the next one. Do not take a double dose.
Condition Constraints: The medicine may be taken with or without food. Do not take Dolopar with any other medication containing paracetamol/acetaminophen to prevent exceeding the maximum daily dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dolopar (Paracetamol)

Evidence for Reducing Fever (Pyrexia)

Research exploring how symptoms change over time has often evaluated Paracetamol in the context of elevated body temperature. Studies conducted during periods of increased symptom activity, primarily Randomized Controlled Trials (RCTs) and Systematic Reviews, have measured the change in core body temperature and patient-reported outcomes describing perceived discomfort. These studies was evaluated in both adult and pediatric populations.

Studies monitored short-term temperature measurements in comparison to control groups. However, for specialized groups, such as critically ill patients, research examining temporary physiological imbalance has yielded mixed findings. Data show patterns related to temperature measurements, but evidence is limited and findings were mixed regarding the impact on major high-level outcomes (such as survival or length of hospital stay) in these particular groups.

Evidence for Acute Mild-to-Moderate Pain

Paracetamol was studied for outcomes related to physical discomfort across a wide range of acute scenarios. The research base features numerous short-term, placebo-controlled RCTs applied in trials assessing short-term or episodic symptom patterns, often summarized in large Meta-analyses. Study populations included healthy adults and patients with conditions associated with acute or disruptive episodes, such as post-operative pain or dental procedures.

Research monitored short-term changes in pain intensity scores in comparison to placebo across many acute models. This evidence contributes to the body of knowledge where outcomes reflect daily functioning or activity level. Studies also explored Paracetamol when used in combination products, where research described how symptom intensity was monitored.

Research Gaps and Remaining Uncertainties

Research has explored many aspects of Paracetamol's effects, but specific gaps and limitations persist. The certainty remains low for the effects of Paracetamol on major clinical outcomes (e.g., mortality, organ failure) in severely ill patients. Furthermore, research exploring short-term symptom changes has not established a consistent difference in outcomes for certain conditions, notably acute low back pain.

The overall evidence quality varies across studies, and while there is considerable data on acute effect patterns, there is limited information for long-term outcomes across all indications. Follow-up durations were limited in the highest-quality trials, and the sample sizes were modest for specific, complex patient subgroups. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly, and evidence highlights what is known—and what is still uncertain—about the medicine.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dolopar (FAQ)

Q: What is the main difference between Dolopar and other similar over-the-counter options?

A: Dolopar's active ingredient, paracetamol (or acetaminophen), belongs to the analgesic and antipyretic class. Official product information indicates that unlike medicines known as non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol has only minor activity against inflammation. Its function is primarily to manage pain and lower a high body temperature through its effects in the central nervous system.

Q: Does Dolopar cause sleepiness or drowsiness?

A: Official labeling for combination products containing the active ingredient often notes that they may also contain caffeine, which acts as a stimulant. Because of this, side effects listed may include being restless, agitated, nervous, or having difficulty sleeping (insomnia), rather than causing sleepiness or drowsiness.

Q: How long does it usually take for Dolopar to start working?

A: Studies on the medicine's pharmacokinetics show that after an oral dose, the active ingredient is generally absorbed quickly by the body. The time it takes for the concentration to reach its highest point in the blood, known as peak plasma concentration, is typically between 10 to 60 minutes.

Q: Can people with high blood pressure use Dolopar?

A: Official drug monographs for the active ingredient do not typically list high blood pressure as a contraindication (a condition that prohibits use) for paracetamol alone. Regulatory guidelines indicate that specific combination products may include additional cardiovascular warnings on their labels. Certain groups, such as the elderly, may have factors that require specific precautions.

Q: Is it possible to become dependent on Dolopar?

A: Official guidelines classify the active ingredient in Dolopar as a Non-Opioid Analgesic. The active ingredient in this class is generally not associated with physical dependence or addiction when used according to regulatory instructions.

Q: Does taking Dolopar affect the results of lab tests?

A: Yes, regulatory documents indicate that the active ingredient can interfere with specific laboratory tests. This may include causing false results for certain methods used to measure uric acid or blood glucose (blood sugar) levels in the body.

Q: What is the shelf life of Dolopar?

A: The official shelf life or expiration date for any medicine is determined by the manufacturer based on stability testing. This date is required to be printed clearly on the outer packaging and container. The medicine is regulated not to be used after the expiration date listed.

Q: Is Dolopar gluten-free?

A: The active ingredient itself, paracetamol, does not contain gluten. However, the regulatory documentation lists all excipients (inactive ingredients) in the product, and these ingredients can vary by manufacturer and formulation. The complete list of excipients (inactive ingredients) can be found in the full product information leaflet.

Q: How long does Dolopar stay in your system after you stop taking it?

A: Official pharmacokinetic data shows that the active ingredient is quickly processed by the liver and eliminated by the body. The elimination half-life, which is the time it takes for half of the drug to be removed, is typically short, ranging from 1.5 to 3 hours in adults with normal liver function.

Q: Is Dolopar generally considered safe for older adults?

A: Official information indicates that the active ingredient is generally considered appropriate for use in older adults. However, regulatory guidelines note that certain factors may require a lower maximum daily dose, such as 3,000 mg per 24 hours, especially when used beyond the recommended short duration of use.

Q: What is the difference between the brand name Dolopar and generic versions?

A: Regulatory bodies like the FDA and Health Canada require generic versions to demonstrate bioequivalence to the brand-name product. This regulatory standard confirms that generic medicines contain the identical active ingredient in the same amount and are expected to work the same way in the body.

Q: What does 'contraindication' mean in relation to Dolopar?

A: A contraindication is a medical term used in official documents to define a condition or health status where the medicine must not be used. For Dolopar, the most significant contraindication listed is the presence of severe hepatic impairment or active liver disease, because using the medicine in this state presents a high risk of harm.

Q: Can Dolopar affect a person's mood?

A: As a combination product, official labels may list side effects related to the central nervous system (CNS), especially if caffeine is included. These effects may include feeling nervous, agitated, or having irritation, though severe psychological issues are not commonly listed.

Q: Is it true that taking Dolopar can cause stomach upset?

A: While the active ingredient is known to be less irritating to the stomach than other classes of pain relievers, some official product labels do list minor gastrointestinal issues. These may include general side effects such as nausea and upset stomach.

Q: Does Dolopar interact with natural supplements like vitamins or herbs?

A: Regulatory information advises caution with supplements. Official documents describe that supplements with known liver toxicity may present an increased risk of adverse effects if taken at the same time as the medicine. Additionally, some supplements may change how the active ingredient is metabolized by the body's enzymes.

Q: How is the safety of Dolopar monitored after it is approved?

A: The safety of the medicine is continually monitored through a system called Pharmacovigilance. This involves regulatory agencies (such as the FDA, via the MedWatch program) collecting reports of side effects from healthcare professionals and the public. These reports are continually reviewed to ensure the ongoing safety profile of the medicine.

Q: Do official patient information leaflets for Dolopar address mental health side effects?

A: Official patient information leaflets list any known side effects, including those affecting the central nervous system (CNS). While not typically listing severe psychiatric issues, labels for combination products may include common CNS effects like nervousness, agitation, and insomnia.

Q: Does Dolopar have different rules for use depending on the country?

A: Yes, while the core active ingredient remains the same globally, the regulatory rules governing the medicine can vary significantly by country. These differences may affect the maximum dose per unit, the overall maximum daily limit for use, prescription status, and the specific warning language that must be included on the label.

Q: What is the reason for the age restriction on Dolopar for young children?

A: The restriction on infants and very young children is based on how the medicine is processed by their bodies. Young children have a less efficient process for how their livers metabolize the drug. This difference increases the potential risk of accidental overdose and subsequent toxicity, particularly severe liver damage.

Q: Do the clinical trials for Dolopar include diverse groups of people?

A: Clinical trial data reviewed by regulatory bodies includes both adult and pediatric populations for various indications like pain and fever. These populations represent the groups for which the drug is approved. However, the public-facing documentation often summarizes the general study populations without providing detailed demographic diversity data (e.g., race or ethnicity).

Q: Is Dolopar commonly used for arthritis?

A: The active ingredient in Dolopar is officially indicated for the temporary relief of mild pain, which includes minor arthritis pain. Regulatory guidelines describe that for chronic conditions like osteoarthritis, official use is often focused on short-term temporary pain relief.

How should Dolopar be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling for acetaminophen-containing products, like Dolopar, mandates specific storage conditions to maintain the medicine's potency and stability.

Area	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C. Avoid excessive heat or freezing.
Protection	Keep in the original container, tightly closed, and protect from humidity.
Child Safety	Must be stored out of the sight and reach of children due to the high risk of overdose.
Disposal	Use an official drug take-back program. If unavailable, mix the product with an undesirable substance (e.g., cat litter) and seal before placing in household trash. Do not dispose of the medicine via wastewater.

Dolopar